The active substance of IntrarosaTM is prasterone
, also known as dehydroepiandrosterone (DHEA), a precursor steroid which is converted into oestrogens and androgens.
is not an estrogen, it does not have the boxed warning that all estrogen products are mandated by the FDA to have.
Effects of prasterone
on corticosteroid requirements of women with systemic lupus erythematosus: A double-blind, randomized, placebo-controlled trial.
Side effects such as acne and hirsutism occurred significantly more often among patients taking the prasterone
Petri and her colleagues plan to evaluate the efficacy and safety of prasterone
on BMD in women with lupus as a primary end point in a future 6-month trial.
Lubricants and moisturizers will be not be effective in treating the underlying cause of GSM, which is best addressed with prescription therapies including estrogens and such topical preparations as creams, rings, and tablets, and the newly approved prasterone
(topical dehydroepiandrosterone [DHEA]).
The objectives of the study was to confirm the local beneficial effects of intravaginal Prasterone
on moderate to severe dyspareunia or pain during sexual activity, the most frequent symptom of vulvovaginal atrophy due to menopause or genitourinary syndrome of menopause (GSM).
DHEA, the most abundant steroidal hormone in the body, has been shown to lower TNF-alpha and IL-6 levels in the Prasterone
(GL701) studies with lupus using a pharmaceutical form of DHEA.
MANCHESTER, ENGLAND -- The addition of prasterone
to standard drug therapy for patients with active systemic lupus erythematosus significantly improved or at least stabilized disease activity in a randomized, double-blind study.
, which is the hormone dehydroepiandrosterone (DHEA), was safe and effective for improving systemic lupus erythematosus (SLE) symptoms and cutting the need for steroids in a phase III trial of 346 women with mild to moderate disease, Dr.
Intrarosa, a once-daily vaginal insert containing prasterone
as the active ingredient, was recently approved for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy due to menopause
Endogenous: androstenediol, androstenedione, dihydrotestosterone, prasterone